A major health insurer said it will stop reimbursing patients for use of injectable amniotic-tissue products made by MiMedx Group Inc. and other manufacturers, saying they are considered “experimental, investigational and/or unproven for all indications.”
The decision by Health Care Service Corp., effective Aug. 1, will likely curb the use of products promoted aggressively for an array of ailments including hair loss, erectile dysfunction, knee pain and osteoarthritis.
...